Market Place
Sourcing Support
European Commission approves cystic fibrosis treatment for six to 11-year-olds
11 Jan 2022 //
PHARMATIMES
Vertex Signs Reimbursement Agreement for KAFTRIO+Ivacaftor in Cystic Fibrosis
19 Nov 2021 //
BUSINESSWIRE
Vertex Announces FDA Approvals of TRIKAFTA® , SYMDEKO® and KALYDECO®
21 Dec 2020 //
BIOSPACE
Symkevi/Kalydeco cleared for use in young CF patients
01 Dec 2020 //
PHARMATIMES
Vertex to Present New Data at Virtual Cystic Fibrosis Conferences
24 Sep 2020 //
BUSINESSWIRE
ICER Issues Report& Policy Recommendations on Treatments for Cystic Fibrosis
23 Sep 2020 //
PRESS RELEASE
Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS
26 Aug 2020 //
EUROPEANPHARMACEUTICALREVIEW
EU nod for Vertex CF therapy Kaftrio
24 Aug 2020 //
PHARMATIMES
Vertex and NHS Wales agree on Kaftrio reimbursement
24 Jul 2020 //
PHARMA TIMES
Vertex Announces Expansion of Reimbursement Agreement With NHS KAFTRIO ®
30 Jun 2020 //
PRESS RELEASE
CHMP Grants Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor)
26 Jun 2020 //
BUSINESSWIRE
Amid COVID-19, Vertex lifts sales projections thanks to Trikafta
30 Apr 2020 //
FIERCE PHARMA
Former Vertex CEO Leiden scored $18.8M in 2019
29 Apr 2020 //
FIERCE PHARMA
Vertex’s new cystic fibrosis drug needs to be far cheaper to be cost effective
29 Apr 2020 //
ENDPTS
ICER Releases Evidence Report on Treatments for Cystic Fibrosis
28 Apr 2020 //
ICER-REVIEW
Switzerland reaches reimbursement deal for Vertex CF drugs
22 Apr 2020 //
PRESS RELEASE
Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI®
20 Apr 2020 //
BUSINESSWIRE
Vertex impresses with strong Trikafta launch
01 Feb 2020 //
BIOPHARMADIVE
Vertex deal with Wales expands cystic fibrosis treatment coverage to all of UK
14 Nov 2019 //
REUTERS
Vertex is `humming` with triple combo launch Trikafta underway
31 Oct 2019 //
FIERCE BIOTECH
Phase 3 Results from Two Studies of TRIKAFTA
31 Oct 2019 //
BUSINESSWIRE
Vertex is `humming` with triple combo launch Trikafta underway: analyst
31 Oct 2019 //
FIERCE PHARMA
FDA Approves Cystic Fibrosis Drug Applicable For 90 Percent Of Patients
22 Oct 2019 //
FORBES
FDA approves new breakthrough therapy for cystic fibrosis
22 Oct 2019 //
FDA
Vertex ushers in CF triple combo era with Trikafta approval
22 Oct 2019 //
FIERCE PHARMA
Spanish Government Approves National Reimbursement of ORKAMBI®
21 Oct 2019 //
BUSINESSWIRE
Regulatory Explainer: Everything You Need to Know About FDA’s Priority Review
21 Oct 2019 //
RAPS
Scotland’s cost regulator rejects Vertex cystic fibrosis drugs
18 Aug 2019 //
PHARMAPHORUM
Vertex’ chief Leiden to step down, with CMO named successor
26 Jul 2019 //
PHARMAPHORUM
FDA expands approval of treatment for cystic fibrosis
21 Jun 2019 //
PR NEWSWIRE
Vertex makes choice for all-important CF triple therapy
01 Jun 2019 //
PMLIVE
Vertex chief Leiden snags $18.8M in pay for `extraordinary` 2018
30 Apr 2019 //
FIERCE PHARMA
Vertex cystic fibrosis triple combo therapy succeeds in important trials
07 Mar 2019 //
REUTERS
Vertex an “extreme outlier” in pricing and behaviour, says NHS England
01 Feb 2019 //
PM LIVE
